VEGFR-2-IN-19(Compound 15b)是一种有效的 VEGFR2 抑制剂,可诱导细胞凋亡(apoptosis)并增加细胞内活性氧(reactive oxygen species)水平,因此可用作抗癌剂。
产品编号: MS-A97151 CAS No.: 2456315-41-4 分子式: C21H19N3O2 分子量: 345.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

VEGFR-2-IN-19(Compound 15b)是一种有效的 VEGFR2 抑制剂,可诱导细胞凋亡(apoptosis)并增加细胞内活性氧(reactive oxygen species)水平,因此可用作抗癌剂。

生物实验数据

生物活性 VEGFR-2-IN-19 (Compound 15b) is a potent VEGFR2 inhibitor that induces apoptosis and increases intracellular reactive oxygen species levels, and can therefore be used as an anticancer agent.
IC50 & Target

VEGFR2

 

体外研究
(In Vitro)

VEGFR-2-IN-19 (Compound 15b) (0-100 µM, 48 h) shows antiproliferative activity against cancer cells.
VEGFR-2-IN-19 (0-10 µM, 48 h) inhibits the phosphorylation of VEGFR2 and the Raf/MEK/ERK signaling pathway, induces cell apoptosis, and arrests cell cycle at G0/G1 phase in HT-29 cells.
VEGFR-2-IN-19 (0-10 µM, 12 h) increases intracellular reactive oxygen species level in HT-29 cells.

Cell Cytotoxicity Assay

Cell Line: HT-29 and A549
Concentration: 0-100 µM
Incubation Time: 48 h
Result: Showed antiproliferative activity with IC50 values of 3.38±1.3 µM and 0.63±0.04 µM against HT-29 and A549 cells, respectively.

Western Blot Analysis

Cell Line: HT-29
Concentration: 0, 1, 5, and 10 µM
Incubation Time: 48 h
Result: Effectively inhibited the phosphorylation of VEGFR2 in dose-dependent manner. Suppressed dose-dependently expression of c-Raf, ERK1/2, and MEK and phosphorylation of ERK1/2 (pERK1/2). Up-regulated caspase-3 and Bax expression, down-regulated Bcl-2 expression.

Apoptosis Analysis

Cell Line: HT-29
Concentration: 0, 1, 5, and 10 µM
Incubation Time: 48 h
Result: The total numbers of early and late apoptotic cells were increased significantly relative to that of untreated control cells in dose-dependent manner.

Cell Cycle Analysis

Cell Line: HT-29
Concentration: 0, 1, 5, and 10 µM
Incubation Time: 48 h
Result: Increased the population of cells in sub G1 and G0/G1 phase and decreased the population of cells in S phase.

化学信息

分子量 345.39
分子式 C21H19N3O2
CAS No. 2456315-41-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础